ATE301656T1 - Reverse-turnmimetika und damit zusammenhängendes verfahren - Google Patents

Reverse-turnmimetika und damit zusammenhängendes verfahren

Info

Publication number
ATE301656T1
ATE301656T1 AT00961491T AT00961491T ATE301656T1 AT E301656 T1 ATE301656 T1 AT E301656T1 AT 00961491 T AT00961491 T AT 00961491T AT 00961491 T AT00961491 T AT 00961491T AT E301656 T1 ATE301656 T1 AT E301656T1
Authority
AT
Austria
Prior art keywords
compounds
related method
disclosed
biologically active
reverse turn
Prior art date
Application number
AT00961491T
Other languages
English (en)
Inventor
Marcin Stasiak
Michael Kahn
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Application granted granted Critical
Publication of ATE301656T1 publication Critical patent/ATE301656T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
AT00961491T 1999-09-01 2000-09-01 Reverse-turnmimetika und damit zusammenhängendes verfahren ATE301656T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/388,854 US6294525B1 (en) 1999-09-01 1999-09-01 Reverse-turn mimetics and methods relating thereto
PCT/US2000/024123 WO2001016135A2 (en) 1999-09-01 2000-09-01 Reverse-turn mimetics and methods relating thereto

Publications (1)

Publication Number Publication Date
ATE301656T1 true ATE301656T1 (de) 2005-08-15

Family

ID=23535809

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961491T ATE301656T1 (de) 1999-09-01 2000-09-01 Reverse-turnmimetika und damit zusammenhängendes verfahren

Country Status (10)

Country Link
US (3) US6294525B1 (de)
EP (1) EP1208103B1 (de)
JP (1) JP4958357B2 (de)
KR (1) KR20020029936A (de)
AT (1) ATE301656T1 (de)
AU (1) AU779841B2 (de)
CA (1) CA2384126A1 (de)
DE (1) DE60021898T2 (de)
ES (1) ES2246889T3 (de)
WO (1) WO2001016135A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294525B1 (en) * 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US7008941B2 (en) * 2001-05-16 2006-03-07 Myriad Genetics, Inc. Reverse-turn mimetics and methods relating thereto
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US6943157B2 (en) * 2001-10-09 2005-09-13 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) * 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US6762185B1 (en) 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
WO2003074005A2 (en) 2002-03-01 2003-09-12 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7652007B2 (en) 2003-02-13 2010-01-26 Sanofi-Aventis Deutschland Gmbh Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
US7390814B2 (en) 2003-02-13 2008-06-24 Sanofi-Aventis Deutschland Gmbh Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
DE10305885A1 (de) * 2003-02-13 2004-08-26 Aventis Pharma Deutschland Gmbh Substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2514791A1 (en) * 2003-02-13 2004-08-26 Aventis Pharma Deutschland Gmbh Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments
KR20050111588A (ko) * 2003-02-13 2005-11-25 사노피-아벤티스 도이칠란트 게엠베하 치환된 헥사하이드로피라지노[1,2-ａ]피리미딘-4,7-디온유도체, 이의 제조방법 및 약제로서의 이의 용도
US20050214859A1 (en) 2003-03-03 2005-09-29 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
CN1871239A (zh) 2003-08-28 2006-11-29 (株)中外制药 β－联蛋白/TCF激活转录的调节
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7992103B2 (en) * 2004-04-26 2011-08-02 Microsoft Corporation Scaling icons for representing files
DE102004042441A1 (de) * 2004-08-31 2006-04-06 Sanofi-Aventis Deutschland Gmbh Mit Aminosäuren substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2006101858A1 (en) * 2005-03-18 2006-09-28 Institute For Chemical Genomics Alpha-helix mimetics and methods relating to the treatment of fibrosis
WO2007056593A2 (en) * 2005-11-08 2007-05-18 Choongwae Pharma Corporation α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS
WO2007056513A1 (en) * 2005-11-08 2007-05-18 Institute For Chemical Genomics α-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
JP5530427B2 (ja) 2008-06-06 2014-06-25 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ アルファへリックスミメティック及び関連の方法
US8691819B2 (en) 2008-10-14 2014-04-08 Prism Biolab Corporation Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions
SG175045A1 (en) * 2009-04-15 2011-11-28 Jw Pharmaceutical Corp Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
WO2010128685A1 (en) 2009-05-07 2010-11-11 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
ES2552462T3 (es) 2010-10-14 2015-11-30 Jw Pharmaceutical Corporation Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo
AU2011330768A1 (en) * 2010-11-15 2013-05-30 Merz Pharma Gmbh & Co. Kgaa Dipeptide analogs for treating conditions associated with amyloid fibril formation
WO2012115286A1 (en) 2011-02-25 2012-08-30 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
EP3057590B1 (de) 2013-10-18 2019-11-27 PRISM BioLab Co., Ltd. Behandlung von lungenfibrose mit einem cbp-/catenin-hemmer
CA2964113A1 (en) 2014-10-14 2016-04-21 La Jolla Institute Of Allergy & Immunology Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
US11066420B2 (en) 2017-05-01 2021-07-20 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
AU2023375360A1 (en) * 2022-11-08 2025-05-15 Parmedics, Inc. Small molecule modulators of par2 and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06505486A (ja) 1991-02-07 1994-06-23 モレキュメティクス，リミティド βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
EP0656907A1 (de) 1992-08-06 1995-06-14 Molecumetics, Ltd. Konformationalbeschränkte mimetika von rückwärtsschleifen und peptide, welche dieselben enthalten
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5886186A (en) 1995-10-25 1999-03-23 Versicor, Inc. Synthesis of substituted N-heteroaromatic compounds and methods of use thereof
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6013458A (en) * 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US6294525B1 (en) * 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto

Also Published As

Publication number Publication date
JP2003508399A (ja) 2003-03-04
KR20020029936A (ko) 2002-04-20
JP4958357B2 (ja) 2012-06-20
WO2001016135A3 (en) 2001-09-07
ES2246889T3 (es) 2006-03-01
CA2384126A1 (en) 2001-03-08
EP1208103B1 (de) 2005-08-10
DE60021898D1 (de) 2005-09-15
US20030130168A1 (en) 2003-07-10
US20020065416A1 (en) 2002-05-30
AU7343600A (en) 2001-03-26
US6440955B1 (en) 2002-08-27
AU779841B2 (en) 2005-02-17
DE60021898T2 (de) 2006-05-24
US6294525B1 (en) 2001-09-25
WO2001016135A2 (en) 2001-03-08
EP1208103A2 (de) 2002-05-29

Similar Documents

Publication Publication Date Title
ATE301656T1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
ATE203025T1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
CA2286733A1 (en) Reverse-turn mimetics and methods relating thereto
DE60036123D1 (de) REVERSE-TURN MIMETIKA ALS alpha 4ß INTEGRIN BLOCKER
DE60227093D1 (de) Reverse-turn-mimetika und diese betreffendes verfahren
TR199802344A2 (xx) �kame edilmi� imidazolidin t�revleri
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
ATE425166T1 (de) Amidderivate von 3-phenyldihydropyrimidoä4,5- düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
BR9915940A (pt) Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53
BG66085B1 (bg) Фенилаланинови производни
ATE158580T1 (de) Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
NO20020282D0 (no) Nytt difenylpiperidinderivat
WO2002092010A3 (en) Reverse-turn mimetics and methods relating thereto
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
DE60121431D1 (de) Ein pyridin-n-oxid-derivat und ein prozess zu seiner umsetzung in pharmazeutische wirkstoffe
EA200500882A1 (ru) N-арилсульфонил-3-аминоалкоксииндолы
ATE288919T1 (de) Thiazolopyrimidine und deren verwendung als modulatoren der chemokinrezeptoraktivität
EP1663201A4 (de) Verwendung von neuen 2-oxo-heterozyklischen verbindungen sowie diesen enthaltenden pharmazeutischen zubereitungen
DK0906272T3 (da) Peptider
IT1274654B (it) Associazioni di fermenti lattici e lisati di saccaromiceti loro uso terapeutico e composizioni che le contengono
BRPI0318325B8 (pt) compostos miméticos de beta-fita
DE69934790D1 (de) Octahydro-6, 10-dioxo-6h-pyridazino/1,2-a/ /1,2/ diazepin-1-carbonsäure-derivate, verfahren zu deren herstellung und deren verwendung zur herstellung pharmazeutischer wirkstoffe
DE60233030D1 (de) Tartrat- und phosphatsalz von 3,4-diaminopyridin, pharmazeutische zusammensetzung und deren verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties